Northern Trust Corp Grows Stock Holdings in Glaukos Co. (NYSE:GKOS)

Northern Trust Corp lifted its stake in Glaukos Co. (NYSE:GKOS - Free Report) by 7.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 578,673 shares of the medical instruments supplier's stock after buying an additional 40,052 shares during the quarter. Northern Trust Corp owned about 1.05% of Glaukos worth $86,766,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Quadrant Capital Group LLC lifted its holdings in Glaukos by 3.3% during the fourth quarter. Quadrant Capital Group LLC now owns 2,300 shares of the medical instruments supplier's stock valued at $345,000 after purchasing an additional 73 shares in the last quarter. Mutual of America Capital Management LLC lifted its stake in shares of Glaukos by 1.1% during the 4th quarter. Mutual of America Capital Management LLC now owns 8,353 shares of the medical instruments supplier's stock valued at $1,252,000 after buying an additional 89 shares in the last quarter. HighTower Advisors LLC boosted its holdings in Glaukos by 2.8% in the 4th quarter. HighTower Advisors LLC now owns 3,298 shares of the medical instruments supplier's stock worth $495,000 after buying an additional 91 shares during the period. Louisiana State Employees Retirement System increased its stake in Glaukos by 0.4% in the 4th quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier's stock worth $4,003,000 after buying an additional 100 shares in the last quarter. Finally, Handelsbanken Fonder AB raised its holdings in Glaukos by 0.7% during the fourth quarter. Handelsbanken Fonder AB now owns 14,700 shares of the medical instruments supplier's stock valued at $2,204,000 after acquiring an additional 100 shares during the period. 99.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

GKOS has been the topic of several recent analyst reports. Stephens decreased their target price on Glaukos from $140.00 to $115.00 and set an "overweight" rating on the stock in a research note on Friday, May 2nd. Wells Fargo & Company cut shares of Glaukos from an "overweight" rating to an "equal weight" rating and reduced their price objective for the company from $160.00 to $86.00 in a research report on Thursday, May 1st. Morgan Stanley dropped their target price on shares of Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a research report on Tuesday. Mizuho decreased their price target on shares of Glaukos from $200.00 to $175.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 16th. Finally, Piper Sandler cut their price objective on Glaukos from $180.00 to $165.00 and set an "overweight" rating for the company in a research report on Tuesday, April 15th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $134.67.

Insider Activity at Glaukos

In other Glaukos news, CFO Alex R. Thurman sold 1,520 shares of the stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total transaction of $162,396.80. Following the sale, the chief financial officer now directly owns 53,431 shares in the company, valued at $5,708,568.04. This represents a 2.77 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Tomas Navratil sold 3,416 shares of the business's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the transaction, the insider now owns 72,437 shares of the company's stock, valued at approximately $10,658,380.18. This trade represents a 4.50 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 6.40% of the company's stock.

Glaukos Trading Down 0.7 %

Shares of NYSE GKOS traded down $0.60 during midday trading on Friday, reaching $89.94. 511,969 shares of the stock were exchanged, compared to its average volume of 680,688. Glaukos Co. has a twelve month low of $77.10 and a twelve month high of $163.71. The stock has a market capitalization of $5.14 billion, a P/E ratio of -31.34 and a beta of 0.83. The company has a 50 day simple moving average of $94.87 and a 200 day simple moving average of $127.35. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.11. The firm had revenue of $106.66 million for the quarter, compared to analyst estimates of $102.78 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The business's revenue for the quarter was up 24.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.70) EPS. As a group, equities analysts expect that Glaukos Co. will post -1.08 earnings per share for the current year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.